User profiles for N. Hanna
 | Nader HannaProfessor of Surgery, University of Maryland School of Medicine Verified email at som.umaryland.edu Cited by 8066 |
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies
G Scagliotti, N Hanna, F Fossella, K Sugarman… - The …, 2009 - academic.oup.com
… in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed
versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced …
versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced …
Advances in systemic therapy for non-small cell lung cancer
M Miller, N Hanna - Bmj, 2021 - bmj.com
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) …
numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) …
[PDF][PDF] SPARK: A US cohort of 50,000 families to accelerate autism research
…, M Yinger, N Bardett, N Hanna, N Harris, N Pottschmidt… - Neuron, 2018 - cell.com
The Simons Foundation Autism Research Initiative (SFARI) has launched SPARKForAutism.org,
a dynamic platform that is engaging thousands of individuals with autism spectrum …
a dynamic platform that is engaging thousands of individuals with autism spectrum …
Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy
N Hanna, FA Shepherd, FV Fossella… - Journal of clinical …, 2004 - ascopubs.org
… received at least one cycle of therapy (12 patients received no treatment due to failure to
meet inclusion criteria [n = 2], death from disease or other cause [n = 2], personal conflict […
meet inclusion criteria [n = 2], death from disease or other cause [n = 2], personal conflict […
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
…, JE Leonard, R Raab, RA Newman, N Hanna… - 1994 - ashpublications.org
Murine monoclonal antibody 2B8 specifically recognizes the CD20 phosphoprotein expressed
on the surface of normal B lymphocytes and B- cell lymphomas. The light- and heavy-…
on the surface of normal B lymphocytes and B- cell lymphomas. The light- and heavy-…
Combined effects of angiostatin and ionizing radiation in antitumour therapy
Angiogenesis, the formation of new capillaries from pre-existing vessels, is essential for tumour
progression 1 , 2 , 3 , 4 , 5 . Angiostatin, a proteolytic fragment of plasminogen 6 that was …
progression 1 , 2 , 3 , 4 , 5 . Angiostatin, a proteolytic fragment of plasminogen 6 that was …
Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial
…, N Acquisto, A Mehrle, K Saangeeta, N Hanna… - Jama, 2021 - jamanetwork.com
Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have not …
although the risks and benefits of this intervention among outpatients with COVID-19 have not …
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
N Hanna, PA Bunn Jr, C Langer, L Einhorn… - Journal of clinical …, 2006 - ascopubs.org
… The primary objective was to compare overall survival in extensive-disease SCLC patients
randomly assigned to receive IP (n = 221) or EP (n = 110). Patients were randomly assigned …
randomly assigned to receive IP (n = 221) or EP (n = 110). Patients were randomly assigned …
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
N Hanna, D Johnson, S Temin, S Baker Jr… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on
systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC). Methods …
systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC). Methods …
Immunological events in regressing genital warts
…, HDL Birley, AM Renton, NF Hanna… - American journal of …, 1994 - academic.oup.com
… Regressing warts (n = 14) contained significantly more T lymphocytes (P <.05, Wilcoxon
rank sum test) and macrophages (P <.01) than did nonregressing controls (n = 14). CD4-…
rank sum test) and macrophages (P <.01) than did nonregressing controls (n = 14). CD4-…